subsided. Moreover, the severity of alcohol withdrawal was not so severe which could lead to confusion and inability to understand the implication of indoor treatment.
Patients with serious physical illness including renal dysfunction were excluded from the study thorough physical examination, history, and routine laboratory screening. The baseline investigations were carried out in all 64 patients (33 in baclofen and 31 in lorazepam groups, and it was typing error in Table 1 where it is written as 22 and 23 in baclofen and lorazepam group, respectively).
It was explained to patients about the cost of baclofen versus cost of lorazepam, and once the patients agreed to buy baclofen, only after that they were included in the study, and for those who could not buy any medicine, they were provided free samples by the investigator.
The study protocol was approved by the institutional ethics committee and also registered with the CTRI/2016/01/006525. The current study was conducted in 2011-2013, whereas recent reviews of randomized controlled trials of baclofen suggest caution in view of poor-quality evidence came in 2017-2018. [5, 6] Authors' reply to commentary on "Gulati P, Chavan BS, Sidana A.
Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome"
Sir, Zolpidem has been used in baclofen group for sleep purpose only. Since zolpidem has quick onset of action and short half-life, it is unlikely to affect the pervasive alcohol withdrawal syndrome. [1] Patients with a history of complicated withdrawal was one of the exclusion criteria for the study, and hence, patients with confusion/disorientation were not enrolled for the study; however, two patients, one from each group, developed complicated withdrawal during detoxification and hence excluded from the study. [2] Since caffeine and nicotine dependence is so common with or without alcohol dependence, we did not exclude them. However, patients with nicotine dependence did receive nicotine replacement therapy in the current study.
The index study was conducted in 2011-2013 and most of the studies [3, 4] had used this dose only although we did mention about using higher doses to find any dose-response relationship in the discussion part. [2] Certainly, for comparison of results, time × treatment interaction effects could have been more informative and this is the limitation of the study.
Patients were first screened in the outpatient department and then admitted in the ward only after taking consent from them, and their relative and patients under intoxication were not admitted till the intoxication was 
Successful administration of electroconvulsive therapy in a patient with treatment-resistant schizophrenia and coexisting myasthenia gravis
Sir,
Electroconvulsive therapy (ECT) is an efficacious treatment for resistant schizophrenia. [1] However, the presence of comorbid myasthenia gravis (MG) poses considerable challenge and concerns for administering anesthesia during ECT. [2] To the best of our knowledge, till date, there is only a solitary case reporting the use of ECT in schizophrenia with coexisting MG. [3] Hence, in this case report, we describe successful administration of modified ECT under anesthesia in a patient with treatment-resistant schizophrenia with MG. [4] [AHRS]-34). In view of coexisting MG, noninvasive brain stimulation by inhibiting temporoparietal junction was attempted with transcranial direct current stimulation (10 sessions) and thereafter with repetitive transcranial magnetic stimulation (24 sessions).
CASE REPORT

Ms
As distressing commanding auditory hallucinations persisted despite the above treatments, we considered ECT. A detailed preanesthetic evaluation with bedside pulmonary function testing was conducted to ascertain good pulmonary reserve. Plasma pseudocholinesterase levels and anti-AChAb levels were 11.2 U/ml (normal -4.65-10.44 U/ml) and 8.8 nmol/L, respectively. This was to ensure remission of MG before administering succinylcholine. During the ECT, precautions were taken to achieve adequate muscle relaxation, and the patient was closely monitored to prevent prolonged apnea. We avoided atropine during ECT to prevent cholinergic crises as the patient was on treatment with physostigmine.
She received nine sessions of modified bifrontal ECT on alternate day, three times a week with a charge of 240 mC (at 1.5 times suprathreshold). Intravenous thiopentone 120 mg and succinylcholine 25 mg were used as anesthetic and muscle relaxing agents, respectively. She showed significant improvement in hallucinations (AHRS-22, SAPS-12, and SANS-20); first five sessions of bimonthly maintenance ECTs were given which reduced to 3 monthly sessions thereafter before stopping ECTs. The patient complained of nausea and dizziness on days of ECT in 7 of the total 17 sessions, which were managed symptomatically. Nausea is one of the common self-limiting side effects following ECT and is probably unrelated to MG [5] and possibly secondary to prolonged fasting or anesthetic procedure. It was symptomatically managed with antiemetics. No other adverse events were noted, and over the next 2 months, neurologist reduced physostigmine to 210 mg/day. In
